SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Impact on OS) Read more about SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Impact on OS)
SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Uptake rate) Read more about SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Uptake rate)
Pre-clinical and clinical activity of GIOTRIF® in uncommon EGFR mutations Read more about Pre-clinical and clinical activity of GIOTRIF® in uncommon EGFR mutations
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell-lung cancer: an observational study Read more about Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell-lung cancer: an observational study
Empagliflozin + Metfromin HCl (Jardiance Duo®) Prescribing Information Read more about Empagliflozin + Metfromin HCl (Jardiance Duo®) Prescribing Information
EK22||EMPA-KIDNEY's Further Results on Annual Rate of Change in eGFR Read more about EK22||EMPA-KIDNEY's Further Results on Annual Rate of Change in eGFR
SEREAL||GIOTRIF® safety and effectiveness in the real world Read more about SEREAL||GIOTRIF® safety and effectiveness in the real world
SEREAL||Real-world evidence: GIOTRIF® in Japan Read more about SEREAL||Real-world evidence: GIOTRIF® in Japan
